Navigation Links
Eisai Donates More Than 80 Murals to Hospitals Around the United States

WOODCLIFF LAKE, N.J., Nov. 11 /PRNewswire/ -- Eisai Inc. today announced that it has donated more than 80 pieces of artwork, created by its employees, to hospitals across the United States.

The multi-panel murals were created by more than 1,200 of Eisai's field employees at a "PaintFest" team building event this summer. The event was conducted with the assistance of the Foundation for Hospital Art, which helps companies and organizations create artwork for donation to hospitals. The Foundation provided Eisai with canvasses with the painting templates, instructions and the assistance of professional artists to help participants - many of whom had never painted before - through the process.

Employee activities such as PaintFest fulfill a key tenet of Eisai's human health care mission, which is to give first thought to patients and their families and to increasing the benefits that healthcare provides. Such activities enable employees to connect with the needs of patients and families in an impactful way.

"This was an amazing experience for all at Eisai who participated in PaintFest," said Cynthia Schwalm, President, U.S. Pharmaceuticals, Eisai Inc. "It served as a reminder to each of us what patients and their families go through when they are facing a health issue that has put them in a hospital setting. That something as seemingly simple as a piece of art can really help to alleviate pain, discomfort or anxiety impresses upon us what patients and their families go through, and reminds us how important it is for us to do all we can to help improve the lives of patients and their families."

The Foundation for Hospital Art ( has worked with various volunteers and partners to donate more than 35,000 paintings to more than 2,000 hospitals worldwide since the organization was founded in 1984.

"We were thrilled for the opportunity to work with Eisai in our continued effort to offer comfort to hospital patients," said John Feight, founder and Executive Director of The Foundation for Hospital Art. "It is especially rewarding to work with partners like Eisai, who truly understand the needs of patients and their families, and are dedicated to actively seeking ways to improve the their lives."

Eisai is proud to have the artwork created by its employees on display at a variety of hospitals around the country, including the following:

         Children's Hospital (New Orleans, Louisiana)
         Children's Hospital of Philadelphia (Philadelphia, Pennsylvania)
         Children's Hospital of Pittsburgh of UPMC (Pittsburgh, Pennsylvania)
         Hoboken University Medical Center (Hoboken, New Jersey)
         Kosair Children's Hospital (Louisville, Kentucky)
         Methodist Children's Hospital (San Antonio, Texas)
         Miami Children's Hospital (Miami, Florida)
         Texas Children's Hospital (Houston, Texas)

In addition, Eisai is pleased to have their artwork on display at the Paramus and Ridgewood facilities of the New Jersey nonprofit agency Children's Aid and Family Services.

About Eisai Inc.

Eisai Inc. is a wholly-owned subsidiary of Eisai Corporation of North America. Established in 1995 and ranked among the top-20 U.S. pharmaceutical companies (based on retail sales), the company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business with fiscal year 2008 (year ended March 31, 2009) sales of approximately $3.7 billion. Eisai Inc.'s areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Headquartered in Woodcliff Lake, New Jersey, Eisai Inc. has several R&D facilities in Massachusetts, New Jersey and North Carolina, as well as manufacturing facilities in Maryland and North Carolina. For more information about Eisai, please visit

SOURCE Eisai Inc.

SOURCE Eisai Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Morphotek(R), Inc. and Eisai Corporation of North America Announce FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian Cancer
2. Teikoku Pharma USA and Eisai Co., Ltd. Announce Licensing Agreement for a New 7-Day Transdermal Formulation of Donepezil.
3. Eisai and Bial Announce Partnership Agreement for the European Commercialisation of the Novel Once Daily Anti-Epileptic Zebinix(R)
4. Eisai Inc. and the North American Thrombosis Forum (NATF)* Introduce the DVTeamCare(TM) Hospital Award and Call for Nominations
5. Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes
6. Biologic Drugs, Particularly Centocor/Janssen-Cilags Stelara and Abbott/Eisais Humira, will Drive the Psoriasis Drug Market to $5 Billion by 2017
7. Eisai Inc. Supports Acting Surgeon Generals Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism
8. Eisai Renews Its Commitment to Responsible Healthcare Community Interactions in Accordance with the Revised PhRMA Marketing Code
9. Eisai Inc. and the Alzheimers Association Introduce the C.A.R.E. Pharmacy Award and Call for Nominations
10. Eisai Corporation of North America Announces Appointment of Vice President of U.S. Corporate Communications
11. Sutter Health Donates $255,000 to Help the Hungry This Holiday Season
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... ... 7th Annual 2015 Golden Bridge Business Awards under the New Products and Services ... capex web based sample management software that helps labs organize data ...
(Date:12/1/2015)... ... 01, 2015 , ... For many X-rays taken at hospitals, ... interpretation by the radiologist. The marking utensils are so small, however, they are ... a way to alleviate this problem. , He developed the patent-pending MARK N ...
(Date:12/1/2015)... ... December 01, 2015 , ... McLean, ... been awarded a fixed price per sprint agile development contract to support the ... million over five years, provides software engineering, infrastructure, as well as operations and ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... SACC-USA through membership and leadership since 2008. Gary Bruce, President of PartnerTech North ... Gary has spent a significant amount of time in Sweden since joining PartnerTech ...
(Date:12/1/2015)... ... December 01, 2015 , ... Tympani ... Technology Provider (ATP) status from Cisco. This designation recognizes Tympani as having fulfilled ... Contact Center solutions targeted to the high-end enterprise contact center marketplace. , Ed ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 1, 2015 Russia has always ... 70% of new drugs registered in Europe in ... --> Russia has always been a country ... drugs registered in Europe in 2015 were tested ... Russia has always been a country of choice ...
(Date:12/1/2015)... Dec. 1, 2015 Relmada Therapeutics, Inc. (OTCQB: RLMD), ... chronic pain, announced today that the company will present at ... December 1-3 at the Luxe Sunset Boulevard Hotel in ... CEO of Relmada Therapeutics, will present on Thursday, December 3, ... . Please register at least 10 minutes prior ...
(Date:12/1/2015)...   MabVax Therapeutics Holdings, Inc . (OTCQB: MBVX), ... filed an Investigational New Drug Application (IND) with the ... lead fully human antibody product HuMab 5B1 as a ... initiate the Phase I clinical trial early in 2016. ... The planned Phase I trial will evaluate the safety, ...
Breaking Medicine Technology: